Anatara Lifesciences Advances GaRP-IBS Trial and Anti-Obesity Project

The latest update is out from Anatara Lifesciences Ltd ( (AU:ANR) ).

Anatara Lifesciences has announced that Stage 2 of its GaRP-IBS Phase II trial has entered the database lock process, with headline results expected soon. Despite the trial’s primary efficacy endpoint for IBS-SSS reduction versus placebo likely not being met, secondary endpoints show promise. The company is also progressing its Anti-Obesity Project, with pre-clinical mice studies underway, aiming to develop an oral medication to assist with weight reduction and maintenance.

More about Anatara Lifesciences Ltd

Anatara Lifesciences Ltd is a company focused on developing evidence-based, innovative products to address significant unmet needs in human health, particularly targeting conditions involving the complexity of the gastrointestinal tract (GIT).

YTD Price Performance: -17.02%

Average Trading Volume: 78,816

Technical Sentiment Consensus Rating: Buy

Current Market Cap: A$8.32M

See more insights into ANR stock on TipRanks’ Stock Analysis page.